|
|
Article: Catalytica Pharmaceuticals Obtains Exclusive License for Chiral Technology With Penn State University.
- Article from:
- Business Wire
- Article date:
- February 11, 1998
CopyrightCOPYRIGHT 1998 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Feb. 11, 1998--Catalytica Pharmaceuticals, Inc., a subsidiary of Catalytica, Inc. (NASDAQ:CTAL), today announced it has signed exclusive license and development agreements with The Pennsylvania State University (Penn State) for new chiral pharmaceutical process technology with important potential applications for the development of processes for a broad spectrum of new drugs.
The license agreement grants Catalytica exclusive worldwide rights to commercial development of the university's work in asymmetric catalysis as developed by Penn State Assistant Professor of organic chemistry Xumu Zhang. The license covers all ...
Related newspaper, magazine, and journal articles:
|
|
Article: Catalytica Pharmaceuticals Announces Manufacturing ...
Business Wire;
January 20, 1998 ;
700+ words
... ... WIRE)--Jan. 20, 1998-- Catalytica Pharmaceuticals, Inc., a subsidiary of Catalytica ... represents revenue potential to Catalytica Pharmaceuticals of approximately $17 million ... the agreement with Allergan, Catalytica Pharmaceuticals will produce Elimite, a topical ...
|
|